Continuing Medical Education Credit Information
The American College of Surgeons is accredited by the ACCME to provide continuing medical education (CME) for physicians.
AMA PRA Category 1 Credits™
The American College of Surgeons designates this enduring material for a maximum of 90 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 90 credits meet the requirements for Self-Assessment.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 12 credits meet the requirements for Trauma.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 6 credits meet the requirements for Surgical Critical Care.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 2 credits meet the requirements for Ethics.
Of the AMA PRA Category 1 Credits™ listed above, a maximum of 1 credit meets the requirements for Patient Safety.
SESAP® 16 (Surgical Education and Self-Assessment Program) is intended for general surgeons.
Upon completion of SESAP® 16, participants should be able to:
- Compare their cognitive knowledge at the beginning of the program with evidence-based surgical content for self-assessment purposes,
- Achieve and demonstrate mastery of surgical content to reach predetermined standards across all categories,
- Apply newly acquired knowledge to surgical practice,
- Keep current with surgical advances, and
- Prepare for Recertification Examinations.
Requirements to Earn 90 AMA PRA Category 1 Credits™
To earn continuing medical education (CME) credit, participants must use the SESAP 16 CME Web version. SESAP 16 includes 850 questions across 14 categories. Participants enrolled for CME credit will be asked to read each question, select an answer, and review the corresponding critique and preferred answer. Participants will test their mastery of the content just learned by answering the same questions in a scrambled fashion and must achieve a cumulative score of 80% within 3 attempts. If the score is less than 80%, the learner will be asked to review the incorrect questions and answer those questions again until 80% is achieved. If a score of 80% correct is not achieved after the third round, the learner will be asked to start the section over again.
Participants can claim CME credit for individual categories. If a category has multiple parts, each part must be completed at the 80% level to claim credit for the entire category. Participants may prefer to claim CME credit once after completing all the categories. After achieving a score of 80% for each category, participants will be asked to complete an overall evaluation form and submit data to the ACS using the Internet. Upon successful submission, a CME certificate will be available to print. SESAP 16 is certified for credit through October 2019.
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and authors complete disclosure forms. Members of the planning committee were required to disclose all financial relationships and authors were required to disclose any financial relationship as it pertains to the content of their contributions. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.
The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias. The planning committee members and authors were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias, please advise us of the circumstances on the evaluation.
The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the content.
Tawnya L. Bowles, MD, FACS (Nothing to disclose)
David R. Brenin, MD, FACS (Consultant—Insitec; Principal Investigator—Theraclion)
Clay Cothren Burlew, MD, FACS (Nothing to disclose)
Casey M. Calkins, MD, FACS (Nothing to disclose)
Jeremy W. Cannon, MD, SM, FACS (Nothing to disclose)
Jeffrey G. Chipman, MD, FACS (Nothing to disclose)
Quyen D. Chu, MD, FACS (Nothing to disclose)
Jay J. Doucet, MD, MSc, FRCSC, FACS, RDMS (Consultant honorarium—Ethicon Endo-Surgery, Inc.)
Dan Eisenberg, MD, MS, FACS (Consultant honorarium—Intuitive Surgical, Inc.)
Dina M. Elaraj, MD, FACS (Nothing to disclose)
Charles M. Friel, MD, FACS, FASCRS (Nothing to disclose)
David A. Gerber, MD, FACS (Consultant honorarium—Pathfinder Therapeutics, Inc.)
Nicole S. Gibran, MD, FACS (Principal Investigator—Mölnlycke Health Care; Principal Investigator—Fibrocell; Principal Investigator—Cytori Therapeutics, Inc.)
Kamal M. F. Itani, MD, FACS (Principal Investigator—Sanofi; Principal Investigator—Merck & Co., Inc.; Principal Investigator—Cubist Pharmaceuticals; Research Development and Advisory Board member—Davol, Inc.; Principal Investigator—Dr. Reddy’s Laboratories)
Tari A. King, MD, FACS (Nothing to disclose)
Richard P. M. Koehler, MD, FACS (Nothing to disclose)
COL Robert B. Lim, MD, FACS (Nothing to disclose)
Linda L. Maerz, MD, FACS, FCCM (Nothing to disclose)
David J. Milia, MD, FACS (Article Reviewer honorarium—Oakstone Publishing, LLC)
Forrest O. Moore, MD, FACS (Editor—Wiley-Blackwell)
Leigh A. Neumayer, MD, FACS (Nothing to disclose)
Daryl P. Pearlstein, MD, FACS (Nothing to disclose)
Walter E. Pofahl II, MD, FACS (Nothing to disclose)
Matthew B. Rossi, MD, FACS (Nothing to disclose)
Paul J. Schenarts, MD, FACS (Nothing to disclose)
David G. Sheldon, MD, FACS (Consultant—Intuitive Surgical, Inc.)
Timothy R. Siegel, MD, FACS (Nothing to disclose)
Lance E. Stuke, MD, MPH, FACS (Nothing to disclose)
William W. Turner, Jr., MD, FACS (Nothing to disclose)
J. Patrick Walker, MD, FACS (Nothing to disclose)
Travis P. Webb, MD, MHPE, FACS (Nothing to disclose)
John A. Weigelt, MD, DVM, FACS, Chair (Consultant honorarium—Pfizer, Inc.; Consultant honorarium—Astellas Pharma US, Inc.; Consultant honorarium—Decisio Health)
Richard M. Bell, MD, FACS (Nothing to disclose)
David C. Borgstrom, MD, FACS (Nothing to disclose)
David A. Bull, MD, FACS (Nothing to disclose)
Mary E. Fallat, MD, FACS (Nothing to disclose)
Jason B. Fleming, MD, FACS (Nothing to disclose)
Amy J. Goldberg, MD, FACS (Nothing to disclose)
John B. Hanks, MD, FACS (Nothing to disclose)
Lorrie A. Langdale, MD, FACS (Nothing to disclose)
Lena M. Napolitano, MD, FACS, FCCP, MCCM (Nothing to disclose)
John T. Paige, MD, FACS (Co-editor—Oxford University Press)
Timothy D. Sielaff, MD, PhD, FACS (Nothing to disclose)
David A. Spain, MD, FACS (Nothing to disclose)
James G. Tyburski, MD, FACS (Nothing to disclose)
Daniel Vargo, MD, FACS (Consultant—Allergan, Inc.)
John T. Vetto, MD, FACS (Spouse’s employer—Genentech, Inc.)
Catherine M. Wittgen, MD, FACS (Consultant and endpoint committee member—Bayer HealthCare Pharmaceuticals, Inc.; Speaker honorarium—Organogenesis Inc.)
Ajit K. Sachdeva, MD, FRCSC, FACS (Nothing to disclose)
Patrice Gabler Blair, MPH (Nothing to disclose)
Julia Dudek, MPH (Nothing to disclose)
Chrysa M. Cullather (Nothing to disclose)